Startups
Pharmability is developing TIR-01, a novel immunomodulatory therapy for atopic dermatitis. Pioneering precision medicine from Stockholm, Sweden.
Overview
Location
Sweden
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 24, 2026 | Pharmability completes GMP release of TIR-C clinical trial material ahead of Phase Ib trial | Pharmability completes GMP release of TIR-C clinical trial material ahead of Phase Ib trial Thu, Sep 24, 2026 07:30 CET Report this content Pharmability today announced that clinical trial material for its Phase Ib trial of TIR-C in atopic ... |
| Aug 28, 2026 | Pharmability selects CTC as CRO for its planned Phase Ib study of TIR-C in atopic dermatitis | Pharmability selects CTC as CRO for its planned Phase Ib study of TIR-C in atopic dermatitis Fri, Aug 28, 2026 07:30 CET Report this content Pharmability today announced that it has selected CTC Clinical Trial Consultants AB (CTC) as the co... |
| Jul 21, 2026 | Pharmability approved by the Swedish Medical Products Agency to start Phase Ib trial of TIR-C in atopic dermatitis | Pharmability approved by the Swedish Medical Products Agency to start Phase Ib trial of TIR-C in atopic dermatitis Tue, Jul 21, 2026 09:23 CET Report this content Pharmability has received authorisation from the Swedish Medical Products Age... |
| Jun 5, 2026 | Pharmability submits Clinical Trial Application for first-in-human Phase Ib study of TIR-C in atopic dermatitis | Pharmability submits Clinical Trial Application for first-in-human Phase Ib study of TIR-C in atopic dermatitis Fri, Jun 05, 2026 07:30 CET Report this content Pharmability today announced the submission of a Clinical Trial Application (CTA... |
| Apr 29, 2026 | Pharmability completes toxicology programme with positive results ahead of Phase Ib study | Pharmability completes toxicology programme with positive results ahead of Phase Ib study Wed, Apr 29, 2026 07:30 CET Report this content Pharmability, a biotechnology company developing next-generation treatments for autoimmune skin diseas... |
| Apr 7, 2026 | Agneta Wennerholm joins Pharmability as Consulting Clinical Project Manager | Agneta Wennerholm joins Pharmability as Consulting Clinical Project Manager Tue, Apr 07, 2026 07:30 CET Report this content Pharmability, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today anno... |
| Mar 19, 2026 | TIRmed Pharma Changes Its Name to Pharmability | TIRmed Pharma Changes Its Name to Pharmability Thu, Mar 19, 2026 09:30 CET Report this content TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today announced that it has changed it... |
Reviews 0
FAQ about Pharmability
What has the press written about Pharmability?
Parsers VC has collected 8 articles mentioning Pharmability, among them “Pharmability completes GMP release of TIR-C clinical trial material ahead of Phase Ib trial” (Sep 24, 2026) and “Pharmability selects CTC as CRO for its planned Phase Ib study of TIR-C in atopic dermatitis” (Aug 28, 2026).
Is Pharmability still active?
Yes, Pharmability is active; its latest activity on Parsers VC dates from Oct 6, 2026.